De-escalation of Therapy for Low-Grade Papillary Bladder Tumors With Preserved Long-Term Oncologic Outcomes

No AccessUrology PracticeResearch Letter11 Jun 2024De-escalation of Therapy for Low-Grade Papillary Bladder Tumors With Preserved Long-Term Oncologic Outcomes Harry Herr Harry HerrHarry Herr Corresponding Author: Harry Herr, MD, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065 ([email protected]) View All Author Informationhttps://doi.org/10.1097/UPJ.0000000000000631AboutFull TextPDF Cite Export CitationSelect Citation formatNLMIEEEACMAPAChicagoMLAHarvardTips on citation downloadDownload citationCopy citation ToolsAdd to favoritesTrack Citations ShareFacebookLinked InTwitterEmail References 1. . Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA. 2018; 319(18):1880-1888. doi: 10.1001/jama.2018.4657 Crossref, Medline, Google Scholar 2. . European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol.2022; 81(1):75-94. doi: 10.1016/j.eururo.2021.08.010 Crossref, Medline, Google Scholar 3. . Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial. Eur Urol.2023; 83(6):497-504. doi: 10.1016/j.eururo.2022.08.003 Crossref, Medline, Google Scholar 4. . DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial. J Clin Oncol.2023; 41(2):206-211. doi: 10.1200/JCO.22.00470 Crossref, Medline, Google Scholar 5. . Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder. Eur Urol.2014; 65(1):201-209. doi: 10.1016/j.eururo.2013.08.034 Crossref, Medline, Google Scholar 6. . Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol.2004; 171(2 Pt 1):636-639. doi: 10.1097/01.ju.0000103100.22951.5e Link, Google Scholar 7. . Risk-adapted management of low-grade bladder tumours: recommendations from the international bladder cancer group (IBCG). BJU Int.2020; 125(4):497-505. doi: 10.1111/bju.14995 Crossref, Medline, Google Scholar 8. . Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol.2007; 177(4):1277-1282. doi: 10.1016/j.juro.2006.11.066 Link, Google Scholar Funding/Support: None. Conflict of Interest Disclosures: The Author has no conflicts of interest to disclose. Ethics Statement: This study received Institutional Review Board approval (IRB No. 16-081). Author Contributions: Conception and design: Herr. Critical revision of the manuscript for scientific and factual content: Herr. Data analysis and interpretation: Herr. Drafting the manuscript: Herr. Study designed and conducted by author: Herr. © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Peer Review Report Open Peer Review Report Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Harry Herr Corresponding Author: Harry Herr, MD, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065 ([email protected]) More articles by this author Expand All Funding/Support: None. Conflict of Interest Disclosures: The Author has no conflicts of interest to disclose. Ethics Statement: This study received Institutional Review Board approval (IRB No. 16-081). Author Contributions: Conception and design: Herr. Critical revision of the manuscript for scientific and factual content: Herr. Data analysis and interpretation: Herr. Drafting the manuscript: Herr. Study designed and conducted by author: Herr. Advertisement PDF downloadLoading ...